BPC 157, a gastric-derived pentadecapeptide, shows wide-ranging benefits in preclinical studies for tissue repair, gut disease, and brain disorders, but lacks the human clinical trials needed for regulatory approval.
Zero approved human clinical trialsDespite widespread preclinical evidence and online sales, BPC 157 has not undergone controlled human studies required for FDA approval
What the researchers found
BPC 157 has demonstrated pleiotropic beneficial effects across numerous preclinical models including tissue injury, inflammatory bowel disease, and CNS disorders. Its safety profile appears favorable with few reported side effects. However, it has not been approved by the FDA or other regulatory authorities due to the absence of sufficient human clinical studies. WADA temporarily banned it in 2022, though it is no longer on the banned list. The review also documents significant commercial and patent interest in the compound.
Why it matters
BPC 157 is one of the most popular peptides in the wellness and sports performance communities, widely sold online despite no regulatory approval. This review provides a needed evidence-based assessment — acknowledging the promising preclinical data while emphasizing the critical gap: no controlled human trials. For the many people already using this peptide, and for researchers, this review clarifies what is known versus assumed.
How the study worked
Literature and patent review covering the biological activities, mechanisms of action, toxicity data, and patent landscape for BPC 157.
What this study cannot tell us
This is a literature review, not a clinical study. All reported therapeutic effects come from preclinical (animal) models, which may not translate to humans. The lack of randomized controlled trials in humans is the fundamental limitation — no matter how promising animal data appears. The safety profile, while favorable in preclinical models, has not been rigorously assessed in human populations.
How to read the evidence
This is a comprehensive literature and patent review. While it thoroughly summarizes preclinical evidence, all therapeutic claims are based on animal studies. The complete absence of human clinical trial data means the evidence for human use remains at the preclinical level.
When this study was published
Published in 2025, this review provides the most current summary of BPC 157 evidence, including the WADA banning controversy and recent patent activity.
The bigger picture
BPC 157 represents a broader phenomenon in peptide therapeutics: compounds with impressive preclinical data that gain widespread public use before undergoing proper clinical validation. The gap between animal studies and human evidence is a critical issue in peptide medicine. BPC 157's journey — from gastric juice discovery to online marketplace to WADA scrutiny — illustrates the challenges of regulating peptides in the supplement era.
Questions still open
- Why have no randomized controlled trials of BPC 157 been conducted in humans despite decades of preclinical research?
- What specific mechanisms of action account for BPC 157's apparently broad healing effects across different tissue types?
- Are the BPC 157 products sold online actually bioequivalent to the research-grade peptide used in published studies?
Common questions
Is BPC 157 safe to take?
Why isn't BPC 157 approved if it works so well in animal studies?
Read the original research
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
Pharmaceuticals (Basel, Switzerland), 18(2)
Citation
Józwiak, Michalina; Bauer, Marta; Kamysz, Wojciech; Kleczkowska, Patrycja. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.. Pharmaceuticals (Basel, Switzerland), 18(2). https://doi.org/10.3390/ph18020185